Healthcare consumer and OTC brand company Haleon has hired Richard Manso as its new U.S. chief marketing officer.
His remit is to push for “Haleon’s evolution into a more agile, consumer-centric organization,” according to an April 27 statement.
The company markets a bevy of popular household brands such as Advil, Sensodyne, Tums and Theraflu—and has in recent years become more independent of its pharma parents.
Haleon was once the consumer unit of GSK before the British pharma company spun it out in 2022. Then, in March 2025, Pfizer sold its remaining stake in the company, a long-expected move as the pharma industry in general began to back away from OTC and consumer businesses.
In its fourth-quarter results posted in February, the company reported organic revenue growth of 2.1%, slower than the previous quarter, and was hit, like other companies, by a mild cold and flu season as well as weakening U.S. consumer demand.
Last year, it also launched its “Win as One” strategy, which aims to reach 1 billion more consumers by 2030 and “deliver industry-leading shareholder returns.”
Against this backdrop, Haleon is also looking to transform itself amid what it calls a “significant transformation in consumer health,” one in which customers “increasingly expect seamless, personalized, and on-demand experiences.”
Manso will be tasked with “strengthening modern marketing capabilities across the U.S. business,” Haleon said.
This will see him focus on “priority areas” including Medicare Advantage OTC, GLP-1s (where Haleon helps manage drug side effects), and emerging platforms such as women’s and pediatric health.
“His role will also support Haleon’s broader ambition to build a more connected, insight-led marketing ecosystem that reflects how consumers engage with health today,” the company added.
He most recently comes from Google, where he led B2B marketing programs and helped drive adoption of data- and AI-enabled marketing projects.